ProQR Therapeutics N.V.
PRQRHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframeProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. At a $182.0M market cap, ProQR Therapeutics N.V. ranks as a micro-cap company within healthcare. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Market Cap
$182.0M
Beta
0.20
P/E (TTM)
—
P/E (Fwd)
-2.73
EPS (TTM)
$-0.45
EPS (Fwd)
$-0.47
ROE
-57.4%
ROA
-19.8%
Cash
$117.1M
Total Debt
$15.3M
Free CF
-$19.1M
52W Change
-55.7%
Annual Financials
Cash vs Debt
Where PRQR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, PRQR finished 24.71% below its 150-day moving average ($1.74) and 23.84% below its 200-day moving average ($1.72). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is PRQR overbought or oversold?
At the October 20, 2026 close, PRQR's RSI(14) was 19.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $117.1M in cash comfortably exceeding the $15.3M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$19.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -57.4%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $3.6M (2022) to $15.9M (2025), reflecting a 343% increase over the period.
With a beta below 0.7, ProQR Therapeutics N.V. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. With cash comfortably exceeding debt, PRQR has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing PRQR.